8.21
price up icon1.48%   0.12
after-market 시간 외 거래: 8.10 -0.11 -1.34%
loading
전일 마감가:
$8.09
열려 있는:
$8.12
하루 거래량:
1.94M
Relative Volume:
1.07
시가총액:
$2.45B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-12.06
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+0.98%
1개월 성능:
+12.16%
6개월 성능:
+3.66%
1년 성능:
+27.88%
1일 변동 폭
Value
$8.07
$8.41
1주일 범위
Value
$7.945
$8.41
52주 변동 폭
Value
$6.32
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
명칭
Amneal Pharmaceuticals Inc
Name
전화
908-947-3120
Name
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
직원
5,210
Name
트위터
@amnealpharma
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
AMRX's Discussions on Twitter

AMRX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
8.21 2.45B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
14.60 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.19 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.35 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.37 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.64 20.17B 16.54B -1.64B 749.00M -1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-06 개시 Goldman Buy
2025-02-24 업그레이드 JP Morgan Neutral → Overweight
2024-09-06 업그레이드 JP Morgan Underweight → Neutral
2021-04-07 재개 RBC Capital Mkts Sector Perform
2021-03-08 업그레이드 Goldman Sell → Buy
2020-12-14 업그레이드 Barclays Equal Weight → Overweight
2020-12-14 업그레이드 Guggenheim Neutral → Buy
2020-07-27 개시 Goldman Sell
2020-05-12 업그레이드 Guggenheim Sell → Neutral
2019-12-12 다운그레이드 Raymond James Outperform → Mkt Perform
2019-11-12 다운그레이드 JP Morgan Neutral → Underweight
2019-11-07 다운그레이드 SVB Leerink Outperform → Mkt Perform
2019-07-22 업그레이드 SVB Leerink Mkt Perform → Outperform
2019-07-11 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-07-08 업그레이드 Piper Jaffray Neutral → Overweight
2019-06-11 개시 Barclays Equal Weight
2019-05-21 업그레이드 Raymond James Mkt Perform → Strong Buy
2019-03-20 개시 SunTrust Buy
2019-03-08 다운그레이드 SVB Leerink Outperform → Mkt Perform
2018-12-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2018-10-16 다운그레이드 SunTrust Buy → Hold
2018-08-13 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2018-07-23 개시 Morgan Stanley Overweight
2018-06-22 개시 B. Riley FBR, Inc. Buy
모두보기

Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스

pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor

Jun 11, 2025
pulisher
Jun 10, 2025

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 09, 2025

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Amneal recalls oral antibiotic due to bacterial contamination - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise

Jun 04, 2025
pulisher
Jun 01, 2025

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Jun 01, 2025
pulisher
May 29, 2025

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 29, 2025
pulisher
May 28, 2025

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

May 27, 2025
pulisher
May 26, 2025

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

May 22, 2025
pulisher
May 22, 2025

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

May 21, 2025
pulisher
May 20, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 20, 2025

Amneal Pharmaceuticals Inc (AMRX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Amneal Pharmaceuticals Inc 주식 (AMRX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Patel Gautam
Director
Jun 10 '25
Sale
8.02
56,426
452,537
1,704,050
Shah Nikita
Executive Vice President
May 16 '25
Sale
7.58
49,140
372,481
388,929
$14.43
price up icon 1.05%
$9.18
price up icon 2.80%
$128.00
price up icon 1.84%
$290.91
price up icon 1.24%
drug_manufacturers_specialty_generic RDY
$14.94
price down icon 0.60%
$16.64
price down icon 0.72%
자본화:     |  볼륨(24시간):